Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Medigenomix Licenses Amplification Technology from Orion Diagnostica

NEW YORK (GenomeWeb News) – Eurofins Mediogenomix has licensed co-exclusive rights to Orion Diagnostica's strand invasion-based amplification (SIBA) technology, the firms announced today.

Espoo, Finland-based Orion Diagnostica owns the global rights for the SIBA isothermal nucleic acid detection technology in all fields, the partners noted. Financial and other terms of the agreement were not disclosed.

"The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins," Peter Persigehl, managing director of Eurofins Medigenomix, which is part of the Eurofins Scientific group. "The cooperation will allow us to broaden Eurofins' portfolio with innovative analytical solutions particularly in the area of DNA-based authenticity testing for food and related products."

The SIBA technology relies on the recombinase-dependent invasion of an oligonucleotide into the target nucleic acid, leading to dissociation of the double-stranded nucleic acid. This enables specific primers to amplify the target exponentially by the action of the polymerase, according to Orion.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.